Withings unveils $129 Move ECG smartwatch with activity and sleep tracking, and ECG monitoring that is awaiting FDA clearance, available in Q2 2019
The analog-faced smartwatch uses three electrodes to measure ECGs. — Withings has had a tumultuous couple of years.
Context & Ripple Effects
Withings has spent five years walking its analog-faced hybrids downmarket: the original Activité launched at $450 and was reviewed as too expensive for the mass market (TechCrunch's verdict), followed by the cheaper Activité Pop, the $170 Activite Steel, and the $70 e-ink Go. The Move ECG continues that price slide while reversing the feature direction — instead of stripping sensors out, it adds three-electrode ECG monitoring to a $129 watch.
The catch is regulatory: the ECG function is announced ahead of FDA clearance, so the headline medical capability may not be live when the watch ships in Q2 2019. That makes Withings one of the smaller players betting its differentiation on a cleared medical feature rather than on screen size or apps.
First-order effects
- Buyers get activity and sleep tracking at launch, but the ECG feature's availability hinges on FDA clearance arriving before or after the Q2 2019 ship date — a gap Withings will have to manage publicly.
- At $129, Withings undercuts the premium pricing that defined its earlier Activité line, repositioning the brand from watch-enthusiast niche toward mass-market health hardware.
Second-order effects
- Rivals selling ECG and other clinical-grade features at flagship prices face a price-floor challenge: if a $129 analog watch carries the same marquee sensor, the feature stops justifying premium hardware.
- The FDA becomes the pacing item for wearable roadmaps — the same clearance pipeline later seen with sleep apnea detection approvals for Apple and Samsung devices determines which vendors can advertise medical features and when.
Third-order effects
- Consumer wearables are converging with regulated medical devices, shifting competitive advantage from industrial design and battery life toward whoever can clear and maintain FDA authorizations.
- If the pattern holds, the FDA's stated fast-track posture for digital health lowers the barrier for small hardware makers to ship diagnostic features, widening the field beyond Apple, Samsung, and Google.
The trend: Wearables are migrating from lifestyle tracking to regulator-cleared medical features, with the FDA's clearance cadence — not component costs — setting the pace of feature rollouts across price tiers.